CD4 and myeloid sarcoma: Disruption to the peripheral homeostasis of CD4+ T-cell populations has been proposed to contribute to the manifestation of both MS and PML, with natalizumab treatment disrupting the balance in a manner that favors the expansion of autoreactive T-cells over virus-specific T-cells (75).